[go: up one dir, main page]

EP0759979A4 - Antisense inhibition of hepatitis c virus - Google Patents

Antisense inhibition of hepatitis c virus

Info

Publication number
EP0759979A4
EP0759979A4 EP95919104A EP95919104A EP0759979A4 EP 0759979 A4 EP0759979 A4 EP 0759979A4 EP 95919104 A EP95919104 A EP 95919104A EP 95919104 A EP95919104 A EP 95919104A EP 0759979 A4 EP0759979 A4 EP 0759979A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
virus
antisense inhibition
antisense
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95919104A
Other languages
German (de)
French (fr)
Other versions
EP0759979A1 (en
Inventor
Takaji Wakita
Jack R Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0759979A1 publication Critical patent/EP0759979A1/en
Publication of EP0759979A4 publication Critical patent/EP0759979A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95919104A 1994-05-10 1995-05-08 Antisense inhibition of hepatitis c virus Withdrawn EP0759979A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24038294A 1994-05-10 1994-05-10
US240382 1994-05-10
PCT/US1995/005812 WO1995030746A1 (en) 1994-05-10 1995-05-08 Antisense inhibition of hepatitis c virus

Publications (2)

Publication Number Publication Date
EP0759979A1 EP0759979A1 (en) 1997-03-05
EP0759979A4 true EP0759979A4 (en) 1999-10-20

Family

ID=22906305

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95919104A Withdrawn EP0759979A4 (en) 1994-05-10 1995-05-08 Antisense inhibition of hepatitis c virus

Country Status (4)

Country Link
US (1) US6001990A (en)
EP (1) EP0759979A4 (en)
JP (1) JPH10503364A (en)
WO (1) WO1995030746A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
IT1297096B1 (en) * 1997-12-03 1999-08-03 Sorin Diagnostics S R L METHOD FOR THE DETECTION OF SINGLE HELIX DNA ANALYTES
EP1002878A3 (en) * 1998-11-19 2003-11-12 Tosoh Corporation Hepatitis C Virus RNA-binding oligo DNA and method preparing it
KR20080023768A (en) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 RNA sequence specific mediator of RNA interference
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2002125688A (en) * 2000-10-30 2002-05-08 Tosoh Corp Oligonucleotides and detection method for sensitive detection of hepatitis C virus
MXPA03004836A (en) 2000-12-01 2005-09-08 Max Planck Gesellschaft SMALL RNA MOLECULES THAT MEDIATE RNA INTERFERENCE.
AU2002227252A1 (en) * 2000-12-01 2002-06-11 Cornell Research Foundation Animal model for flaviviridae infection
AU2002311897A1 (en) * 2001-05-09 2002-11-18 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
CA2936534C (en) 2001-07-23 2021-01-26 The Board Of Trustees Of Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
EP1352960A1 (en) * 2002-04-12 2003-10-15 Viruvation B.V. Antiviral therapy on the basis of RNA interference
US20040024193A1 (en) * 2002-07-26 2004-02-05 Williams Gregg T. Method of detecting and quantifying hepatitis C virus
JP4603356B2 (en) * 2002-07-26 2010-12-22 アボット・ラボラトリーズ Method for detecting and quantifying hepatitis C virus
WO2004011647A1 (en) * 2002-07-26 2004-02-05 Chiron Corporation Modified small interfering rna molecules and methods of use
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) * 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
FR2848572B1 (en) * 2002-12-12 2005-12-09 Univ Joseph Fourier INHIBITOR MOLECULES OF PROTEIN SYNTHESIS OF HEPATITIS C VIRUS AND METHOD FOR SCREENING THESE INHIBITORY MOLECULES
JP4545091B2 (en) * 2003-01-24 2010-09-15 財団法人 東京都医学研究機構 Oligoribonucleotide or peptide nucleic acid that inhibits the function of hepatitis C virus
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
SG173218A1 (en) * 2003-06-12 2011-08-29 Alnylam Pharmaceuticals Inc Conserved hbv and hcv sequences useful for gene silencing
JP4943322B2 (en) 2004-05-04 2012-05-30 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ Methods and compositions for reducing the amount of viral genome in target cells
AU2011250867A1 (en) * 2004-05-04 2011-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for reducing viral genome amounts in a target cell
WO2006031901A2 (en) * 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
EP2772541A3 (en) 2004-09-24 2014-09-24 Alnylam Pharmaceuticals Inc. Targeting opposite strand replication intermediates of hepatitis C virus by RNAi
WO2007052629A1 (en) * 2005-11-01 2007-05-10 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and pharmaceutical composition
WO2007084567A2 (en) * 2006-01-17 2007-07-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus
WO2007112753A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2261333B1 (en) 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
DK2149605T3 (en) 2007-03-22 2013-09-30 Santaris Pharma As Short RNA antagonist compounds to modulate the desired mRNA
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
WO2009043354A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Combination treatment for the treatment of hepatitis c virus infection
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
JP2012505657A (en) * 2008-10-15 2012-03-08 ソマジェニックス インク． Short hairpin RNA for gene expression inhibition
ES2599979T3 (en) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for the treatment of HCV patients who do not respond to interferon
EP2454371B1 (en) 2009-07-13 2021-01-20 Somagenics, Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
CN105164261B (en) 2013-05-01 2022-03-18 莱古路斯治疗法股份有限公司 Compounds and methods for enhanced cellular uptake
AU2014300981B2 (en) 2013-06-27 2017-08-10 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting PCSK9
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
WO2019217369A1 (en) 2018-05-08 2019-11-14 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
AR114551A1 (en) 2018-08-13 2020-09-16 Alnylam Pharmaceuticals Inc COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
CA2104649A1 (en) * 1992-08-25 1994-02-26 Makoto Seki Antisense compounds complementary to hcv genome
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
WO1994008002A2 (en) * 1992-09-28 1994-04-14 Chiron Corporation Methods and compositions for controlling translation of hcv proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4789734A (en) * 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0545913B1 (en) * 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
EP0384566A3 (en) * 1989-01-27 1991-11-13 The Wistar Institute Amplification of htlv-1 sequences from multiple sclerosis patients
JP2656995B2 (en) * 1989-03-17 1997-09-24 カイロン コーポレイション NANBV diagnostics
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
CA2089761A1 (en) * 1990-08-29 1992-03-01 Elaine Defreitas Method and compositions for diagnosing and treating chronic fatique immunodysfunction syndrome
EP0516859A1 (en) * 1990-11-29 1992-12-09 Toray Industries, Inc. Non-a non-b hepatitis virus antigen protein
JPH06508026A (en) * 1991-05-08 1994-09-14 カイロン　コーポレイション HCV genome sequence for diagnosis and treatment
JPH06508024A (en) * 1991-06-10 1994-09-14 ラッキー・リミテッド Hepatitis C diagnostic reagents and vaccines
KR950014915B1 (en) * 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
JP3688290B2 (en) * 1991-11-21 2005-08-24 コモン サーヴィシス エージェンシー Hepatitis C virus test
EP0642592A4 (en) * 1992-05-29 1997-01-02 Abbott Lab Ligase chain reaction starting with rna sequences.
JP2778886B2 (en) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Hepatitis C virus core antigen protein and diagnostic method and kit using the same
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
CA2104649A1 (en) * 1992-08-25 1994-02-26 Makoto Seki Antisense compounds complementary to hcv genome
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
WO1994008002A2 (en) * 1992-09-28 1994-04-14 Chiron Corporation Methods and compositions for controlling translation of hcv proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO9530746A1 *
WAKITA T ET AL: "INHIBITION OF HEPATITIS C VIRUS ANTIGEN EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST 5' NONCODING REGION RIBOSOMAL BINDING SITES", HEPATOLOGY, vol. 18, no. 4, PART 02, 1 October 1993 (1993-10-01), pages 77A, XP000603285, ISSN: 0270-9139 *
WAKITA T ET AL: "SPECIFIC INHIBITION OF HEPATITIS C VIRUS EXPRESSION BY ANTISENSE SPECIFIC OLIGODEOXYNUCLEOTIDES. IN VITRO MODEL FOR SELECTION OF TARGET SEQUENCE.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 19, 13 May 1994 (1994-05-13), pages 14205 - 14210 142, XP000604710, ISSN: 0021-9258 *
WU G Y ET AL: "DELIVERY SYSTEMS FOR GENE THERAPY", BIOTHERAPY, vol. 3, 1991, pages 87 - 95, XP000764198, ISSN: 0921-299X *

Also Published As

Publication number Publication date
EP0759979A1 (en) 1997-03-05
US6001990A (en) 1999-12-14
JPH10503364A (en) 1998-03-31
WO1995030746A1 (en) 1995-11-16

Similar Documents

Publication Publication Date Title
EP0759979A4 (en) Antisense inhibition of hepatitis c virus
EP0837951A4 (en) Antisense inhibition of hepatitis b virus replication
PL324906A1 (en) Vaccines against viral hepatitis of c type
PL321966A1 (en) Vaccine against viral hepatitis of b type
HU9402822D0 (en) Antisense oligonucleotide inhibition of papillomavirus
NZ290318A (en) Compositions comprising antisense oligonucleotides for use against hepatitis b viral replication
AP9200412A0 (en) Compounds and methods for inhibition of hiv and related viruses
GB9415369D0 (en) Mutant virus
EP0973510A4 (en) Use of amantadine for treatment of hepatitis c
NZ307494A (en) Lymphokine capable of inhibiting immunodeficiency viruses
PL312692A1 (en) New derivatives of dialkoxy-pyridinol-benzimidazole
EP0833668A4 (en) Inhibition of hepatitis b replication
AU2970595A (en) Inhibition of virus by nitric oxide
ZA964446B (en) Oligonucleotides specific for hepatitis c virus
GB9425604D0 (en) Peptides effective for diagnsis of hepatitis C infection
GB9006924D0 (en) Prognosis of hepatitis infection
GB9209669D0 (en) Novel plant virus sequences
EP0879055A4 (en) Inhibition of viral replication
GB8914680D0 (en) Prevention of aid virus
HU0400424D0 (en) Hepatitis virus vaccines
GB9420956D0 (en) Virus
GB9108030D0 (en) An antisense"aids"virus
IL114891A0 (en) 3-substituted-2- oxindoles as inhibitors of viral replication
IL132848A0 (en) Treatment of hepatic cirrhosis
GB9213362D0 (en) Hcv-3 virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19990903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE ES FR GB IT NL

RBV Designated contracting states (corrected)

Designated state(s): CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20010704

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050908